Abstract: Objective To explore the short-term curative effect of transcatheter arterial chemoembolization (TACE) with ¹³¹I mentuximab perfusion in the treatment of patients with primary liver cancer (PLC) and influencing factors of prognosis. Methods Eighty-four patients with PLC were admitted to our hospital from August 2016 through December 2017, and were divided into control group and observation group, with 42 cases in each group. The patients with PLC in the control group were treated with TACE, and those in the observation received TACE and ¹³¹I mentuximab perfusion. All patients were followed-up for 12 months. The risk factors affecting prognosis were analyzed by multivariate Logistics regression analysis. Results At the end of three months, the remission rate and control rate in the observation group were 73.8% and 90.5%, significantly higher than 50.0% and 73.8%, respectively, in the control(P<0.05);the incidence of side effects was 28.6% in the observation group, not significantly different compared to 33.3% in the control group (P>0.05); serum alpha-fetoprotein level in the observation group was (418.7±67.3) ng/ml, much lower than [(504.7±71.5) ng/ml, P<0.05] in the control, and serum albumin level was (37.7±3.4) g/L, significantly higher than [(34.2±3.3) g/L, P<0.05] in the control; at the end of 12 month, seven patients(16.7%)in the observation died, while twelve patients (28.6%)in the control died (P<0.05); the multivariate Logistics regression analysis showed that the portal vein tumor thrombus, tumor diameter greater than 5 cm and advanced stage of TNM were the risk factors of poor prognosis(OR=2.354, P=0.027; OR=2.670, P=0.011; OR=3.071, P=0.004). Conclusion The short-term curative effect of TACE with ¹³¹I mentuximab perfusion in the treatment of patients with PLC is promising, and some factors such as portal vein tumor thrombus, large tumor diameter and advanced TNM staging might hint poor prognosis.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, ¹³¹I mentuximab, Prognosis